News Breaks |
|
|
| February 6, 2013 |
| 12:06 EDT |  | BBEP, SFLY, CHRW, BPI, NVS | High option volume stocks: BBEP SFLY CHRW BPI NVS
|
|
|
News For BBEP;SFLY;CHRW;BPI;NVS From The Last 14 Days Check below for free stories on BBEP;SFLY;CHRW;BPI;NVS the last two weeks. |
|
|
| May 17, 2013 |
| 16:20 EDT |  | NVS | Novartis drug Afinitor extended time without disease progression in women
 Subscribe for More Information |
|
| May 16, 2013 |
| 08:11 EDT | | NVS | Novartis says no intention of pursuing Actavis, Bloomberg reports
Subscribe for More Information |
|
| May 15, 2013 |
| 19:37 EDT |  | NVS | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 18:17 EDT | | NVS | Novartis weighs possible bid for Actavis, DJ reports
Subscribe for More Information |
|
| May 13, 2013 |
| 16:02 EDT |  | SFLY | Shutterfly files to sell $220M in convertible senior notes
|
|
| 10:09 EDT |  | CHRW | On The Fly: Analyst Downgrade Summary
Subscribe for More Information |
|
| 06:44 EDT | | CHRW | C.H. Robinson downgraded to Neutral from Buy at UBS
Subscribe for More Information |
|
| May 10, 2013 |
| 17:10 EDT |  | BPI | Bridgepoint Education revises Q1 EPS to 49c from 43c
Subscribe for More Information |
|
| 10:01 EDT | | BPI | House GOP proposes reform of student loan interest rates, The Hill says
Subscribe for More Information |
|
| 05:42 EDT | | NVS | Novartis drug Ilaris approved by FDA
Subscribe for More Information |
| |
| May 9, 2013 |
| 15:31 EDT | | CHRW | C.H. Robinson at lows, down more than 2% after cutting dividend to 33c per share
|
|
| 15:29 EDT | | CHRW | C.H. Robinson cuts dividend 2c to 33c per share
Subscribe for More Information |
|
| 06:00 EDT | | SFLY | Acacia Research subsidiary enters into settlement agreement with Shutterfly
Subscribe for More Information |
|
| May 8, 2013 |
| 13:59 EDT | | BPI | For-profit education stocks rally after Grand Canyon results
Subscribe for More Information |
|
| 09:45 EDT |  | CHRW | C.H. Robinson falls sharply after earnings miss
Subscribe for More Information |
|
| 07:28 EDT |  | CHRW | C.H. Robinson price target lowered to $48 from $55 at FBR Capital
Subscribe for More Information |
|
| May 7, 2013 |
| 16:26 EDT | | CHRW | C.H. Robinson reports Q1 EPS 64c, consensus 69c
Subscribe for More Information |
|
| May 6, 2013 |
| 16:23 EDT | | NVS | Array to start first company-led Phase 3 trial with MEK162
Array (ARRY) announced the planned start of its first company-led Phase 3 trial with MEK162 in low-grade serous ovarian cancer. This is the third MEK162 pivotal trial that is expected to initiate in 2013 and one of five pivotal trials Array expects to begin in 2013 on Array-invented products. Novartis (NVS), who is co-developing MEK162 with Array, previously stated that Phase 3 trials in NRAS-mutant melanoma and BRAF-mutant melanoma are expected to start this year and AstraZeneca has announced its plans to initiate two registration trials with selumetinib, a MEK inhibitor invente (AZN) d by Array, in KRAS-mutant non-small cell lung cancer and in thyroid cancer. Array also recently released initial data on its wholly-owned hematology drug, ARRY-520, from a combination trial with VelcadeŽ (bortezomib) in patients with relapsed or refractory multiple myeloma (MM), showing that the drug was generally well-tolerated and showed initial signs of activity in this heavily pretreated population. |
|
| 15:03 EDT | | CHRW | C.H. Robinson May volatility elevated into Q1 and outlook
Subscribe for More Information |
|
| 07:09 EDT | | BPI | Bridgepoint Education reports Q1-end student enrollment 78,782
Reports Q1 new student enrollments 13,300. |
| |
|
|
|
|
